Characteristics and treatment outcomes of newly diagnosed epilepsy in older people: A 30-year longitudinal cohort study
Bshra Ali A Alsfouk, Haris Hakeem, Zhibin Chen, Matthew Walters, Martin J Brodie, Patrick Kwan
Epilepsia | WILEY | Published : 2020
OBJECTIVES: To describe the clinical characteristics and evaluate the long-term treatment outcomes in older people with newly diagnosed epilepsy over the past 30 years. METHODS: We included patients newly diagnosed with epilepsy and commenced on antiseizure medications (ASMs) at age 65 years or older between July 1982 and October 2012 at the Western infirmary in Glasgow, Scotland. They were followed up until April 2016 or death. Seizure freedom was defined as no seizure for at least 1 year on unchanged medication at the last follow-up. RESULTS: A total of 201 patients (median age 73 years, 59% male) were included. The median duration from initial seizure to starting treatment was 8 months (i..View full abstract
Awarded by Early Career Fellowship from the National Health and Medical Research Council (NHMRC) of Australia
Awarded by Medical Research Future Fund Fellowship
Zhibin Chen is supported by an Early Career Fellowship from the National Health and Medical Research Council (NHMRC) of Australia (GNT1156444). He/his institution has received consultancy fees and/or research grants from Arvelle Therapeutics and UCB Pharma. Matthew Walters reports receiving research grants from the Chief Scientist Office (UK), Mitsubishi Pharma, and the Stroke Association (UK). He has undertaken consultancy work for Myokardia Inc, Alnylam Pharmaceuticals Inc, and Resverlogix Corp. Martin Brodie has received speaker and consultancy fees from UCB, Eisai, Xenon, and Arvelle Therapeutics, outside the submitted work. Patrick Kwan is supported by a Medical Research Future Fund Fellowship (MRF1136427). His institution has received research grants from Biscayne Pharmaceuticals, Eisai, GW Pharmaceuticals, LivaNova, Novartis, UCB Pharma, and Zynerba outside the submitted work; he has received speaker fees from Eisai, LivaNova, and UCB Pharma outside the submitted work. The remaining authors have no conflict of interest. We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.